-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

Benzinga·05/12/2026 11:20:05
Listen to the news
Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.